Drug Trial Radar · NCT05355298
ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
May 31, 2022
Primary completion
Feb 1, 2027
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- Amplia Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line patients with unresectable or metastatic pancreatic cancer. Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Part B will determine the efficacy of the AMP945 regimen at the RP2D, and will be run as a Simon Two-stage design; Stage 1 will enrol 26 participants. If ≤5 of the 26 participants show an objective response, then recruitment will be paused and a detailed analysis of futility will be performed. If the study is deemed futile, recruitment will cease. If the study is determined to be not futile or \>5 of the 26 participants show an objective response, recruitment will continue, and an additional 24 participants will be enrolled in Stage 2.
Conditions
- Pancreatic Cancer
- PDAC
- Pancreatic Ductal Adenocarcinoma
Interventions
AMP945 ascending dosesDrug
Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
AMP945 RP2DDrug
Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of StudyTime frame: From first dose of study drug to end of study, an expected average of 6 months
- Part A: Determination of RP2DTime frame: After Cycle 1 (28 days) for each Part A cohort
- Part B: efficacy of AMP945Time frame: Imaging every 56 days per participant, with an expected average duration of 6 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
GenesisCare
St Leonards, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Gallipolli Medical Research Foundation
Greenslopes, Queensland, Australia
Epworth Healthcare
Box Hill, Victoria, Australia
Monash Health
Clayton, Victoria, Australia
Epworth Healthcare
Richmond, Victoria, Australia
Western Health
St Albans, Victoria, Australia
National Cancer Centre
Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Severence Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Centre
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.